The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
CombiGene AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.38% SEK3.36
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 66.53 mill |
| EPS: | -1.800 |
| P/E: | -1.870 |
| Earnings Date: | May 23, 2024 |
| SharesOutstanding: | 19.80 mill |
| Avg Daily Volume: | 0.0435 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.870 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -1.870 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK4.22 (25.64%) SEK0.862 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 3.16 - 3.56 ( +/- 6.04%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK3.36 (3.38% ) |
| Volume | 0.0615 mill |
| Avg. Vol. | 0.0435 mill |
| % of Avg. Vol | 141.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For COMBI.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
COMBI.ST
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.